Bleeding Risk Following Total Shoulder Arthroplasty in Patients Using Selective Serotonin Reuptake Inhibitors.

BACKGROUND: The purpose of the current study is to evaluate the association between selective serotonin reuptake inhibitor (SSRI) use and the risk of perioperative bleeding and blood transfusion following total shoulder arthroplasty. METHODS: The PearlDiver (PearlDiver Technologies, Colorado Springs, CO, USA) Mariner170 database was queried to conduct this retrospective cohort study. Patients were included if they were over 18 years, had anxiety or depression, and underwent primary TSA. Eligible patients were stratified by SSRI use and 1:1 case-control matched by age, gender, Charlson Comorbidity Index (CCI), and relevant comorbidities. Patient demographics and 30-day postoperative outcomes, including bleeding, transfusion, deep venous thrombosis, or pulmonary embolism, were extracted and compared across cohorts. RESULTS: The SSRI and control groups each contained 3,346 patients who underwent anatomic or reverse TSA. For each group, the mean age was 67.45 ± 7.44 years with 2,410 (72.03%) males and a mean CCI of 1.04 ± 1.07. There were no significant differences (p